Get the Stockscreener App
0.00
100.00%
-63.48
Catalent Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$63.48
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$11.52B
Revenue:
$4.42B
Net Income/Loss:
$-413.00M
P/E Ratio:
0.00
EPS:
-2.27
Net Cash Flow:
$99.00M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$63.50
Catalent Inc Stock (CTLT) Company Profile
Name
Catalent Inc
Sector
Phone
(732) 537-6200
Address
14 SCHOOLHOUSE ROAD, SOMERSET, NJ
Compare CTLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTLT
Catalent Inc
|
0.00 | 11.52B | 4.42B | -413.00M | 99.00M | -2.27 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Catalent Inc Stock (CTLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-16-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-05-23 | Upgrade | Argus | Hold → Buy |
| Jul-20-23 | Initiated | Wells Fargo | Equal Weight |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jun-14-23 | Downgrade | Jefferies | Buy → Hold |
| May-22-23 | Downgrade | JP Morgan | Overweight → Neutral |
| May-15-23 | Downgrade | Deutsche Bank | Buy → Hold |
| May-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-17-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Nov-07-22 | Downgrade | Argus | Buy → Hold |
| Nov-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-16-21 | Initiated | Barclays | Overweight |
| Dec-10-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jun-25-20 | Initiated | Argus | Buy |
| Apr-21-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Oct-17-19 | Resumed | Stephens | Overweight |
| Aug-28-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-21-19 | Upgrade | Jefferies | Hold → Buy |
| Apr-16-19 | Upgrade | UBS | Neutral → Buy |
| Nov-07-18 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-09-18 | Initiated | UBS | Neutral |
| Mar-28-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-21-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-06-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-17 | Initiated | Needham | Hold |
| Sep-08-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Dec-01-16 | Initiated | Goldman | Neutral |
| Oct-20-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-21-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-20-16 | Upgrade | BofA/Merrill | Neutral → Buy |
View All
Catalent Inc Stock (CTLT) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq
Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news
Lisata Therapeutics announces research license with Catalent - MSN
Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive financial news
Lisata, Catalent partner for cancer drug research - Investing.com
Lisata, Catalent partner for cancer drug research By Investing.com - Investing.com South Africa
Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus
Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire
Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com
Game-Changing Cancer Treatment Alliance: Lisata and Catalent Combine Breakthrough Technologies - Stock Titan
Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board - marketscreener.com
Catalent's Journey Of Continuous Improvement For CSV Excellence - Bioprocess Online
Trump’s Tariff Threat Sparks Race to Find US Drug Manufacturers - Yahoo Finance
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
CRDMO Market Research 2025: A Highly Competitive $328 Billion Market by 2029 with Lonza Group, WuXi, Catalent, Sai Life Sciences, Syngene, Jubilant Biosys, and Thermo Fisher Scientific Leading - Yahoo Finance
Unit Dose Manufacturing Industry Report 2025-2030: Market to Cross $150.6 Billion Led by Catalent, Unither Pharmaceuticals, and Thermo Fisher Scientific - Yahoo Finance
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) Investigation - ACCESS Newswire
Healthcare CMO Market Projected To Witness Substantial Growth, 2025-2032: Lonza Group, Catalent, Inc., Aenova - EIN News
Per-Encounter Medical Market to Witness Remarkable Growth with Catalent Inc., Smiths Medical Inc., Cardinal Health - openPR
Catalent announces new board appointments - ROI-NJ
Catalent Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors - citybiz
Catalent Announces New Board Appointments - Business Wire
Novo to grow Catalent? Rumor mill spins amid Trump tariff threat - BioProcess Insider
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Ardena Acquires Catalent’s Drug Product Manufacturing Facility in Somerset, NJ - Contract Pharma
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America - Yahoo Finance
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
How Novo’s Acquisition Of Catalent Cleared European Regulators - Citeline
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards? - MSN
Catalent (NYSE:CTLT) Now Covered by StockNews.com - Defense World
Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent’s Analytical Services Laboratory in Research Triangle Park - ACCESS Newswire
Catalent's Award-Winning Innovations and Community Engagement Initiatives - Pharmaceutical Technology
Catalent to make CAR-T for Galapagos; Kindeva gets $129M for nerve agent antidote - Endpoints News
Catalent backs decentralised manufacture of Galapagos’ CAR-T therapy - MSN
Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US - Indian Pharma Post
Catalent to support Galapagos’ decentralized cell therapy approach - The Pharma Letter
Catalent to Support Galapagos’ Decentralized CAR-T Therapy Trials - Contract Pharma
Catalent, Inc. (NYSE:CTLT) Given Average Rating of “Hold” by Analysts - Defense World
Catalent Inc Stock (CTLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.70%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):